Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation

Carcinogenesis

Volumn 32, Issue 7, 2011, Pages 1013-1024

  Bharadwaj, Uddalak ^a   Marin Muller, Christian ^a   Li, Min ^a,b   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESOTHELIN; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL 2; RECOMBINANT INTERLEUKIN 6; SMALL INTERFERING RNA; SOLUBLE INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; WEDELOLACTONE;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; PANCREAS CANCER; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79960068710     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr075     Document Type: Article

References (47)

1. Hassan,R. et al. (2004) Mesothelin: a new target for immunotherapy. Clin. Cancer Res., 10, 3937-3942.
2. Li,M. et al. (2008) Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol. Cancer Ther., 7, 286-296.
3. Bharadwaj,U. et al. (2008) Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol. Cancer Res., 6, 1755-1765.
4. Uehara,N. et al. (2008) Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol. Cancer Res., 6, 186-193.
5. Adachi,Y. et al. (2006) Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int. J. Cancer., 119, 1303-1311.
6. Yeh,H.H. et al. (2006) Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene, 25, 4300-4309.
7. Cavarretta,I.T. et al. (2007) The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene, 26, 2822-2832.
8. Lin,M.T. et al. (2001) IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of antiapoptotic gene mcl-1. Carcinogenesis, 22, 1947-1953.
9. Hodge,D.R. et al. (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer., 41, 2502-2512.
10. Bellone,G. et al. (2006) Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol. Immunother., 55, 684-698.
11. Okada,S. et al. (1998) Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn. J. Clin. Oncol., 28, 12-15.
12. Lang,S.A. et al. (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin. Cancer Res., 13, 6459-6468.
13. Friess,H. et al. (1999) Growth factors and cytokines in pancreatic carcinogenesis. Ann. N. Y. Acad. Sci., 880, 110-121.
14. Miyamoto,Y. et al. (2001) Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res., 21, 2449-2456.
15. Coussens,L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
16. Naugler,W.E. et al. (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med., 14, 109-119.
17. Bollrath,J. et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15, 91-102.
18. Bromberg,J. et al. (2009) Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell, 15, 79-80.
19. Fujino,S. et al. (1996) Interleukin 6 is an autocrine growth factor for normal human pleural mesothelial cells. Am. J. Respir. Cell Mol. Biol., 14, 508-515.
20. Zhang,D. et al. (2011) Deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 knockout mice. Cancer Sci., 102, 720-727.
21. Bharadwaj,U. et al. (2007) Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res., 67, 5479-5488.
22. Ebrahimi,B. et al. (2004) Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer, 101, 2727-2736.
23. Aggarwal,B.B. et al. (2006) Inflammation and cancer: how hot is the link? Biochem. Pharmacol., 72, 1605-1621.
24. Alberti,L. et al. (2004) IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int. J. Cancer., 111, 653-661.
25. Bihl,M. et al. (1998) Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am. J. Respir. Cell Mol. Biol., 19, 606-612.
26. Nishimoto,N. et al. (1994) Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J. Exp. Med., 179, 1343-1347.
27. Okamoto,M. et al. (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res., 57, 141-146.
28. Rose-John,S. et al. (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets., 11, 613-624.
29. Cheng,W.F. et al. (2009) High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br. J. Cancer., 100, 1144-1153.
30. Cheng,W.F. et al. (2007) Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer, 110, 420-431.
31. Masamune,A. et al. (2009) Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut, 58, 550-559.
32. Kulbe,H. et al. (2007) The inflammatory cytokine tumor necrosis factoralpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res., 67, 585-592.
33. Lee,H.G. et al. (1995) Peritoneal lavage fluids stimulate NIH3T3 fibroblast proliferation and contain increased tumour necrosis factor and IL-6 in experimental silica-induced rat peritonitis. Clin. Exp. Immunol., 100, 139-144.
34. Althoff,K. et al. (2000) Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur. J. Biochem., 267, 2624-2631.
35. Mullberg,J. et al. (1999) Generation and function of the soluble interleukin-6 receptor. Biochem. Soc. Trans., 27, 211-219.
36. Matthews,V. et al. (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem., 278, 38829-38839.
37. Varga,V.L. et al. (2001) gp130-specific antisense oligonucleotides inhibit IL-6 signal inducing junB mRNA transcription in the human hepatoma cell line, HepG2. Cell Biol. Int., 25, 835-840.
38. Amati,M. et al. (2008) Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat. Res., 655, 52-58.
39. Topley,N. et al. (1993) Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int., 43, 226-233.
40. Witowski,J. et al. (1996) Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney Int., 50, 1212-1223.
41. Serve,H. et al. (1991) Studies on the interaction between interleukin 6 and human malignant nonhematopoietic cell lines. Cancer Res., 51, 3862-3866.
42. Lee,E.J. et al. (2007) Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer., 120, 1046-1054.
43. Kuilman,T. et al. (2008) Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 133, 1019-1031.
44. Galvez,A.S. et al. (2009) Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol. Cell. Biol., 29, 104-115.
45. Liu,J. et al. (2004) A genetically defined model for human ovarian cancer. Cancer Res., 64, 1655-1663.
46. Fukamachi,K. et al. (2009) An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. Biochem. Biophys. Res. Commun., 390, 636-641.
47. Wallner,L. et al. (2006) Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgendependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res., 66, 3087-3095.